(Q47411033)

15 January 2018

title

The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs (English)

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

27 March 2024

main subject

pharmaceutical science

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

27 March 2024

author name string

Henrik Agersø

1

1 reference

15 January 2018

Wolfgang Koechling

2

1 reference

15 January 2018

Magnus Knutsson

3

1 reference

15 January 2018

Rolf Hjortkjaer

4

1 reference

15 January 2018

Mats O. Karlsson

5

1 reference

PubMed ID

14592699

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14592699

27 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

15 January 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0928098703002227?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

https://api.elsevier.com/content/article/PII:S0928098703002227?httpAccept=text/plain

27 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

European Journal of Pharmaceutical Sciences

27 March 2024

published in

1 reference

15 January 2018

volume

20

1 reference

15 January 2018

page(s)

335-340

1 reference

15 January 2018

issue

3

1 reference

15 January 2018

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Development of GnRH antagonists for prostate cancer: new approaches to treatment

27 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach

27 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue

27 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

27 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.

27 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

27 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

27 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice

27 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

The LHRH antagonist cetrorelix: a review

27 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.EJPS.2003.08.001

27 March 2024

Identifiers

1 reference

15 January 2018

PubMed ID

14592699

1 reference

15 January 2018